BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 29950864)

  • 1. Whole-body MRI versus
    Wang D; Huo Y; Chen S; Wang H; Ding Y; Zhu X; Ma C
    Onco Targets Ther; 2018; 11():3597-3608. PubMed ID: 29950864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma.
    Ferrari C; Minoia C; Asabella AN; Nicoletti A; Altini C; Antonica F; Ficco M; Guarini A; Maggialetti N; Rubini G
    Hell J Nucl Med; 2014; 17 Suppl 1():40-9. PubMed ID: 24392468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-body diffusion-weighted magnetic resonance imaging versus FDG-PET/CT for initial lymphoma staging: systematic review on diagnostic test accuracy studies.
    Regacini R; Puchnick A; Shigueoka DC; Iared W; Lederman HM
    Sao Paulo Med J; 2015; 133(2):141-50. PubMed ID: 25789779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body magnetic resonance imaging (WB-MRI) in lymphoma: State of the art.
    Albano D; Bruno A; Patti C; Micci G; Midiri M; Tarella C; Galia M
    Hematol Oncol; 2020 Feb; 38(1):12-21. PubMed ID: 31486520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body MRI versus an [
    Spijkers S; Littooij AS; Kwee TC; Tolboom N; Beishuizen A; Bruin MCA; Enríquez G; Sábado C; Miller E; Granata C; de Lange C; Verzegnassi F; de Keizer B; Nievelstein RAJ
    Eur Radiol; 2021 Dec; 31(12):8925-8936. PubMed ID: 34021390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.
    Albano D; Patti C; La Grutta L; Agnello F; Grassedonio E; Mulè A; Cannizzaro G; Ficola U; Lagalla R; Midiri M; Galia M
    Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas.
    Maccioni F; Alfieri G; Assanto GM; Mattone M; Gentiloni Silveri G; Viola F; De Maio A; Frantellizzi V; Di Rocco A; De Vincentis G; Pulsoni A; Martelli M; Catalano C
    Radiol Med; 2023 May; 128(5):556-564. PubMed ID: 37145214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now.
    Galia M; Albano D; Tarella C; Patti C; Sconfienza LM; Mulè A; Alongi P; Midiri M; Lagalla R
    Eur Radiol; 2018 Mar; 28(3):1187-1193. PubMed ID: 29018927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
    Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
    Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
    Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
    Albano D; Patti C; Lagalla R; Midiri M; Galia M
    J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study.
    Spijkers S; Littooij AS; Kwee TC; Tolboom N; Beishuizen A; Bruin MCA; Elias SG; van de Brug T; Enríquez G; Sábado C; Miller E; Granata C; de Lange C; Verzegnassi F; Greer MC; de Keizer B; Nievelstein RAJ
    Eur Radiol; 2021 Mar; 31(3):1494-1504. PubMed ID: 32880696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of naive indolent lymphoma using whole-body diffusion-weighted imaging and T2-weighted MRI: results of a prospective study in 30 patients.
    Hong GS; Chae EJ; Ryu JS; Chae SY; Lee HS; Yoon DH; Suh C
    Cancer Imaging; 2021 Jan; 21(1):5. PubMed ID: 33413685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT.
    Herrmann K; Queiroz M; Huellner MW; de Galiza Barbosa F; Buck A; Schaefer N; Stolzman P; Veit-Haibach P
    BMC Cancer; 2015 Dec; 15():1002. PubMed ID: 26699124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin's lymphoma: a comparison with multi-modality reference standard including
    Latifoltojar A; Punwani S; Lopes A; Humphries PD; Klusmann M; Menezes LJ; Daw S; Shankar A; Neriman D; Fitzke H; Clifton-Hadley L; Smith P; Taylor SA
    Eur Radiol; 2019 Jan; 29(1):202-212. PubMed ID: 29948084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of Outcome.
    De Paepe KN; Van Keerberghen CA; Agazzi GM; De Keyzer F; Gheysens O; Bechter O; Wolter P; Dierickx D; Janssens A; Verhoef G; Oyen R; Koole M; Vandecaveye V
    Radiol Imaging Cancer; 2021 Mar; 3(2):e200061. PubMed ID: 33817648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of diffusion-weighted MRI and [
    Morakote W; Baratto L; Ramasamy SK; Adams LC; Liang T; Sarrami AH; Daldrup-Link HE
    Eur Radiol; 2024 Jan; 34(1):643-653. PubMed ID: 37542653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
    Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
    Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M
    Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.